Economic Burden of Clostridioides difficile Infection in European Countries
© 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG..
Clostridioides difficile infection (CDI) remains a considerable challenge to healthcare systems worldwide. Although CDI represents a significant burden on healthcare systems in Europe, few studies have attempted to estimate the consumption of resources associated with CDI in Europe. The reported extra costs attributable to CDI vary widely according to the definitions, design, and methodologies used, making comparisons difficult to perform. In this chapter, the economic burden of healthcare facility-associated CDI in Europe will be assessed, as will other less explored areas such as the economic burden of recurrent CDI, community-acquired CDI, pediatric CDI, and CDI in outbreaks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1435 |
|---|---|
| Enthalten in: |
Advances in experimental medicine and biology - 1435(2024) vom: 04., Seite 1-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reigadas, Elena [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
C. difficile infection |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-3-031-42108-2_1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366660896 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366660896 | ||
| 003 | DE-627 | ||
| 005 | 20240211231950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-3-031-42108-2_1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM366660896 | ||
| 035 | |a (NLM)38175468 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reigadas, Elena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Economic Burden of Clostridioides difficile Infection in European Countries |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive license to Springer Nature Switzerland AG. | ||
| 520 | |a Clostridioides difficile infection (CDI) remains a considerable challenge to healthcare systems worldwide. Although CDI represents a significant burden on healthcare systems in Europe, few studies have attempted to estimate the consumption of resources associated with CDI in Europe. The reported extra costs attributable to CDI vary widely according to the definitions, design, and methodologies used, making comparisons difficult to perform. In this chapter, the economic burden of healthcare facility-associated CDI in Europe will be assessed, as will other less explored areas such as the economic burden of recurrent CDI, community-acquired CDI, pediatric CDI, and CDI in outbreaks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a C. difficile infection | |
| 650 | 4 | |a Economic burden | |
| 650 | 4 | |a Economic costs | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a Length of stay | |
| 700 | 1 | |a Vázquez-Cuesta, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Bouza, Emilio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in experimental medicine and biology |d 1971 |g 1435(2024) vom: 04., Seite 1-12 |w (DE-627)NLM000012157 |x 0065-2598 |7 nnns |
| 773 | 1 | 8 | |g volume:1435 |g year:2024 |g day:04 |g pages:1-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-3-031-42108-2_1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1435 |j 2024 |b 04 |h 1-12 | ||